A newly published study is stirring up questions about the relationship between Depo-Provera, and other progestogen-only injectable contraceptives, and the risk of HIV acquisition among HIV-negative women. The study triggered a wave of headlines and tweets that boiled down the complexities and caveats of this analysis into an oversimplified statement: Depo increases women’s risk of HIV by 40 percent.
14 January 2015 | RH Reality Check
Lancet analysis finds 40% increase in infection risk for women using birth control jab compared with other hormonal methods.
09 January 2015 | The Guardian
Preexposure prophylaxis (PrEP) with tenofovir or tenofovir/emtricitabine proved as effective in women using the injectable hormonal contraceptive depot medroxyprogesterone acetate (DMPA) as in women using no hormonal contraceptive. The same proved true of men whose female sex partners were using DMPA.
07 January 2015 | International AIDS Society
An increasingly important issue is whether certain ART regimens are expected to have drug interactions when used with certain hormonal contraceptive methods. In theory, an interaction could affect the efficacy of either medication, or cause side effects or toxicity. If contraceptive efficacy decreases, the chances of contraceptive failure, unintended pregnancy, and the accompanying consequences increase.
10 December 2014 | K4Health
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.
14 November 2014 | Science Speaks
University of Washington researchers have created a discreet, quick-dissolving tampon out of silk-line fibers to protect women from HIV. The researchers would ideally like to develop a tampon to protect against HIV, herpes, and pregnancy — an all-in-one shield against the risks of sex. This could prove especially useful in developing countries, where women may not have easy access to other kinds of birth control.
04 November 2014 | Healthline News
Contrary to guidelines issued by the World Health Organization, new research has found that HIV-positive women receiving one of the most common forms of drug therapy should be able to use at least some forms of oral contraceptives for birth control.
30 October 2014 | Oregon State University
LGBT academic Ian Lekus compares the furore around PrEP with the one that met the development of the contraceptive pill: "Acknowledged or not, PrEP users — and for that matter, three decades-plus of HIV/AIDS activism — build directly on how the Pill’s early adopters challenged the presumed omniscience of medical authorities. The experiences of the Pill’s first users also remind us to keep a critical eye trained on those institutions and narratives that circumscribe the quest for balancing health, desire, and autonomy."
25 September 2014 | Nursing Clio
We call on the donors to ensure the ECHO trial is fully funded without additional budget cuts or delays. ECHO is a randomized clinical trial that would look at whether the three options—Depo, Jadelle, and the copper intrauterine device—affect HIV-negative women’s risk of acquiring HIV.
15 September 2014 | RH Reality Check
In the rush to save babies from HIV infection and treat their mothers, experts warn that a key element of HIV prevention is being neglected in Africa – contraceptives for HIV positive women.
15 August 2014 | Inter Press Service